share_log

10-Q: Quarterly report

10-Q: Quarterly report

10-Q：季度報表
美股sec公告 ·  05/15 16:19
Moomoo AI 已提取核心訊息
TC BioPharm, a clinical-stage biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of £3.3 million, a significant increase from the £0.6 million net loss in the same period the previous year. This was attributed to a decrease in research and development expenses, which dropped by 33% to £1.3 million, and a decrease in administrative expenses by 4% to £2.1 million. The company's cash and cash equivalents stood at £1.0 million as of March 31, 2024. TC BioPharm's business development focused on advancing its pipeline of unmodified allogeneic GD-T therapies and next-generation GD CAR-T treatments. The company's future plans include continuing its clinical trials, expanding its manufacturing capabilities, and potentially commercializing its product candidates. However, the report indicates substantial doubt about the company's ability to continue as a going concern, with current cash reserves expected to fund operations only into July 2024. Additional funding will be necessary to sustain operations beyond that point.
TC BioPharm, a clinical-stage biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of £3.3 million, a significant increase from the £0.6 million net loss in the same period the previous year. This was attributed to a decrease in research and development expenses, which dropped by 33% to £1.3 million, and a decrease in administrative expenses by 4% to £2.1 million. The company's cash and cash equivalents stood at £1.0 million as of March 31, 2024. TC BioPharm's business development focused on advancing its pipeline of unmodified allogeneic GD-T therapies and next-generation GD CAR-T treatments. The company's future plans include continuing its clinical trials, expanding its manufacturing capabilities, and potentially commercializing its product candidates. However, the report indicates substantial doubt about the company's ability to continue as a going concern, with current cash reserves expected to fund operations only into July 2024. Additional funding will be necessary to sustain operations beyond that point.
臨床階段的生物製藥公司TC BioPharm公佈了截至2024年3月31日的季度財務業績。該公司的淨虧損爲330萬英鎊，較去年同期的60萬英鎊淨虧損大幅增加。這歸因於研發費用減少，下降了33％，至130萬英鎊，管理費用減少了4％，至210萬英鎊。截至2024年3月31日，該公司的現金和現金等價物爲100萬英鎊。TC BioPharm的業務發展側重於推進其未改良的異基因GD-T療法和下一代GD CAR-T療法的產品線。該公司的未來計劃包括繼續進行臨床試驗，擴大其製造能力，並可能將其候選產品商業化。但是，該報告顯示，人們對該公司繼續經營的能力存在嚴重懷疑，目前的現金儲備預計要到2024年7月才能爲運營提供資金。在此之後，將需要額外的資金來維持業務。
臨床階段的生物製藥公司TC BioPharm公佈了截至2024年3月31日的季度財務業績。該公司的淨虧損爲330萬英鎊，較去年同期的60萬英鎊淨虧損大幅增加。這歸因於研發費用減少，下降了33％，至130萬英鎊，管理費用減少了4％，至210萬英鎊。截至2024年3月31日，該公司的現金和現金等價物爲100萬英鎊。TC BioPharm的業務發展側重於推進其未改良的異基因GD-T療法和下一代GD CAR-T療法的產品線。該公司的未來計劃包括繼續進行臨床試驗，擴大其製造能力，並可能將其候選產品商業化。但是，該報告顯示，人們對該公司繼續經營的能力存在嚴重懷疑，目前的現金儲備預計要到2024年7月才能爲運營提供資金。在此之後，將需要額外的資金來維持業務。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息